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Abstract We describe a phyllodes tumor of borderline
malignancy in the labium majus of a 49-year-old woman.
The histogenetic origin of phyllodes tumors in the vulva is
controversial. Strong immunoreactivity for NY-BR-1, a
novel breast differentiation antigen, was demonstrated
within the epithelial components of the phyllodes tumor.
A similar expression pattern was observed in mammary-
like glands of the vulva. These findings provide further
evidence that phyllodes tumors of the vulva might derive
from mammary-like glands in the labium majus or from
ectopic breast tissue.
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Introduction
Mammary glands are modified apocrine glands arising
along the mammary ridges, which appear on either side of
the body in the fourth week of embryonal development,
persisting only for a week. Remnants of these ridges can
result in an arborising mesh of canals, giving rise to
aberrant lactiferous ducts at anatomical sites other than the
breast in the form of ectopic breast tissue. A fully formed
mammary gland arising in the vulvar region was first
described in 1872 by Hartung in a 30-year-old woman at
the left labium majus. Since then, various benign and
malignant variants of epithelial mammary tumors have been
described, and ectopic mammary glands have been
regarded as the tissue of origin of these neoplasms.
It has been reported that histologic changes in the
ectopic breast tissue are, in general, similar to hormon-
induced lesions in the breast occurring during puberty and
early pregnancy [9]. Benign or malignant tumors of the
vulva other then squamous neoplasms occur very rarely
[20]. Whether proliferative processes mimicking breast
lesions in the anogenital region evolve from remnants of
the mammary ridges or originate from local adnexal
structures, e.g. eccrine, sebaceous and apocrine glands of
the skin, from mammary-like glands (MLGs) of the vulva,
or whether they arise in neoplastically transformed ectopic
breast tissue are still a question of debate.
In this report, we present a rare case of a phyllodes tumor
in the vulva. We show that the recently described breast
differentiation antigen NY-BR-1 is expressed in this tumor
at an extramammary site as well as in MLGs of the vulva.
Clinical history
A 49-year-old hysterectomized, smoking (60 package
years) but otherwise healthy perimenopausal patient pre-
sented with a rapidly growing mass at the labium majus
near the clitoris on the right side. The patient was treated
with 17-β-estradiole for menopausal symptoms. The
symptoms were spotting and discharge. The lesion, which
developed within 5 weeks, measured 3.7 cm in diameter
and appeared sharply circumscribed. The tumor was
excised surgically. A second resection was performed
2 months after the first tumor excision.
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Materials and methods
The surgical specimen was fixed in 4% buffered formalin
and submitted entirely for histology. Two-micrometer
sections from the paraffin-embedded tissue were taken for
immunohistochemistry and haematoxylin and eosin (H&E)
staining (Superfrost Plus, Menzel, Braunschweig, Ger-
many). Immunostaining for mAb NY-BR-1 [21]; Ludwig
Institute, New York) was performed on Ventana Benchmark
(Ventana Medical Systems, Tucson, AZ) at a dilution of
1:400 (concentration, 2 μg/ml), MIB-1 (DAKO Diagnos-
tics, dilution 1:20), CD34 (Serotec, dilution 1:50), estrogen
receptor (6F11, Ventana dispenser), and progesterone
receptor (1A6, Ventana dispenser).
Results
On gross examination, the specimen appeared as a polypoid
firm lesion, with an uneven surface. The polypwas covered by
normal epidermis. The cut surface was light gray, showing a
firm sharply demarked tumor of 3.7 cm in diameter (Fig. 1).
The histological examination of the tumor revealed a
subcutaneous mass consisting of a predominant stromal
component, interrupted by leaf-like spaces lined by an
epithelial component with bilayered epithelia consisting of
myoepithelial and secretory cells, which directly harbored
to the surface and covered the same one superficially. The
surface of the tumor was focally ulcerated, without direct
infiltration through neoplastic cells (Fig. 2).
The lining was predominantly composed of secretory
(apocrine)-type epithelia and resembled mammary glandu-
lar epithelia. The secretory epithelial cells demonstrated a
strong nuclear and cytoplasmatic immunoreactivity to NY-
BR-1 and a 100% nuclear immunoreactivity for estrogen
and progesterone receptors. No atypia or significant mitotic
activity was present in the epithelial tumor component. The
stroma was hypercellular with spindle-shaped, moderately
pleomorphic cells with pale elongated nuclei and scanty
cytoplasm. Focally, the mitotic activity of the stroma was
increased (three to four mitoses per ten high-power fields,
HPF). The proliferation index was 5% (MIB-1, Ki67). The
neoplastic stroma demonstrated a stronger immunoreactiv-
ity for CD34 than the surrounding subcutaneous connective
tissue. There was a small intraductal papilloma within the
polypoid lesion. Overtly polymorphic stromal cells, necro-
sis or brisk mitotic activity exceeding ten mitoses per ten
HPF were absent. Therefore, the tumor was diagnosed as a
phyllodes tumor with “borderline” malignancy.
Eccrine glands and MLGs were observed adjacent to the
tumor. The latter also showed nuclear and cytoplasmic
reactivity for NY-BR-1.
Because of the incomplete resection and the unpredict-
able behavior of “borderline” phyllodes tumors, a second
resection was performed 2 months after the primary
excision. The resection specimen contained MLGs, regen-
erative tissue with foreign body reaction but no remnants of
the phyllodes tumor.
Discussion
In this report, we describe a phyllodes tumor of the vulva
and discuss its histogenesis in the light of its expression of
the novel breast differentiation antigen NY-BR1.
Various benign and malignant tumors resembling breast
neoplasms have been described in the vulvar region [1–3, 5,
6, 8, 9, 15, 16, 20]. It has been suggested that these tumors
derive from ectopic breast tissue or from MLG.
Cystosarcoma phyllodes of the breast, today preferen-
tially named phyllodes tumor, was first described by
Johannes Müller in 1838 [7]. According to our knowledge,
five phyllodes tumors [4, 14, 17, 18] of the vulva and one
phyllodes tumor of the perineum [13] have been reported.
More than two dozen fibroadenomas of the vulva have been
described, and it has been discussed whether these neo-
plasms arise from skin adherence glands or from ectopic
mammary tissue.
The epithelial cells of the present tumor demonstrate
strong cytoplasmic and nuclear NY-BR-1 immunoreactivi-
ty. NY-BR-1 is a novel mammary differentiation antigen. It
was recently identified by SEREX analysis of a metastatic
breast carcinoma patient [10–12]. The NY-BR-1 gene has
been mapped to chromosome 10p11–12 and is composed of
37 exons. It encodes a peptide of Mr 150,000 to 160,000,
which is regarded as a putative transcription factor. NY-BR-
Fig. 1 Phyllodes tumor of the vulva. Overview (H&E). Typical leaf-
like pattern (scale bar=1 cm)
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1 mRNA expression was found in a high percentage of
breast cancers (84%) and normal breast tissue and at a
much lower level in normal adult testis but not in other
normal tissues [10]. We have recently demonstrated strong
protein expression in mammary glands and in carcinomas
of the breast using immunohistochemistry [21]. Our
findings suggest that the novel monoclonal NY-BR-1
antibody can be used as a surrogate marker for tumors of
breast origin.
The NY-BR-1 expression is a strong argument for a
derivation of the phyllodes tumor of the vulva from MLGs
or from ectopic breast tissue. Further evidence for a
derivation of the phyllodes tumor from MLGs is its
location at the inner side of the labium majus and the
Fig. 2 Phyllodes tumor of the vulva. Histology and immunohisto-
chemistry. A–B Mammary-like glands in the vicinity of the phyllodes
tumor (arrowhead) HE (a) and NY-BR-1 immunohistochemistry (b;
A–B scale bar=1 mm). C–E Detail of stroma with increased mitotic
activity. Arrows indicate two mitoses in one HPF (c); Bilayered
epithelium consisting of myoepithelial- and secretory-cell layers (d );
NY-BR-1 immunoreactivity in cytoplasm and nuclei of secretory
ductal cells (e; C–D scale bar=20 μm). Legend to figures: F–G MLG
in the surroundings of the phyllodes tumor. HE ( f ) and NY-BR-1
(g; F–G scale bar=0.15 mm)
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prominent MLGs in the immediate surroundings. Van der
Putte [19, 20] suggests that vulvar neoplasms resembling
breast tumors most probably arise in MLGs. He observed
that many of these lesions (a) greatly resemble but are not
identical to corresponding lesions of the breast, (b) occur
also in the perineum and around the anus but rarely
elsewhere on the skin and (c) are elements of discussion
concerning their derivation that focus on eccrine or apocrine
glands or their precursor cells rather than on mammary tissue.
He further argues that these features reflect basic elements of
the MLGs that are directly related to eccrine glands and show
apocrine metaplasia. Some MLGs reveal a mammary-type
histology as the predominant feature.
The behavior of phyllodes tumors is difficult to predict
by histology alone. In the breast, phyllodes tumors are
classified into benign, borderline and malignant according
to mitotic rate, nuclear pleomorphism and presence of necrosis.
Because of the increased mitotic activity, the tumor of
our patient was classified as “borderline.” After incomplete
excision of the lesion, an additional resection was
performed to prevent local recurrence.
In summary, we present a phyllodes tumor of the vulva
with strong expression of the breast differentiation antigen
NY-BR-1. MLGs of the vulva also express this antigen and
were abundantly present in close vicinity to the tumor.
Therefore, we speculate that at least some phyllodes tumors
of the vulva are derived from such glands, although we
cannot exclude that ectopic mammary glands are also the
origin of such vulvar tumors.
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